Lung cancer persists throughout the world as a major cause of death. In 2014, data from the
Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer …

Background The role of pembrolizumab in the treatment of poor performance status (PS)
patients remains unclear. Patients and methods We conducted a phase II trial to investigate …

Triple-negative breast cancers (TNBC) are typically resistant to treatment, and strategies that
build upon frontline therapy are needed. Targeting the murine double minute 2 (Mdm2) …

Lung cancer stands as the first cause of death by cancer in the world. Despite the
improvement in patients' outcomes in the past decades through the development of …

Background Randomized phase II and III studies showed the promising results of the
combination of carboplatin/pemetrexed with pembrolizumab in non-squamous non-small …

Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with
locally advanced or metastatic disease. In this setting the goal of treatment is to prolong …

Introduction: Non-small cell lung cancer (NSCLC) remains one of the big cancer killers,
despite the introduction of a number of approved therapeutics in recent times. Pemetrexed is …

Lung cancer (LC) is the leading cause of cancer-related death worldwide, despite a
decreasing incidence rate in recent years, especially in men. Most risk factors for LC could …

Background Osimertinib is a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non …

Background The prognosis of non-small cell lung cancer (NSCLC) patients with bone
metastasis is extremely repulsive. The aim of this study was to potentially characterize the …